Danaher Stock - Analyst consensus snapshot on earnings and growth

Danaher stock sits in the upper mid-cap range of the S&P 500, with Wall Street maintaining a broadly positive stance. Analysts still see upside driven by life-science tools, diagnostics and bioprocessing, even after a period of softer demand.

Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/18/2026, 14:04 UTC. Details in the imprint.

Danaher Corp. (US2358511028) remains a closely watched US life-science and diagnostics group. Analysts continue to publish constructive estimates and price targets for the stock, with consensus pointing to further upside according to current aggregation data.

What current consensus shows

Several data providers compile analyst estimates for Danaher, showing a broadly positive stance. MarketBeat aggregates 25 Wall Street analysts with an average 12-month price target of about $233.61, implying material upside from recent levels.

According to this aggregation, the consensus rating stands at "Moderate Buy", with target prices ranging roughly from $200 at the low end to $275 at the high end. That spread reflects different views on how fast bioprocessing demand and instrument orders normalize.

How analysts frame the story

Analysts generally highlight Danaher’s exposure to biopharma tools, diagnostics and environmental-and-applied solutions. These areas benefit from long-term spending on healthcare and research, even if shorter cycles in lab budgets lead to temporary soft patches.

Net-net, the consensus narrative emphasizes Danaher’s cash generation, portfolio quality and history of disciplined acquisitions. At the same time, commentary points to near-term headwinds in bioprocessing and cautious customer ordering behavior, particularly after the pandemic-driven boom.

How Danaher makes its money

Danaher develops and sells instruments, consumables and software for life sciences, diagnostics and environmental applications. Its portfolio includes well-known platforms such as the Cytiva bioprocessing line and Beckman Coulter analyzers, which generate recurring revenue from consumables and services.

Where the stock trades today

Danaher stock (US2358511028) trades on the New York Stock Exchange at about $177.85 as of 06/17/2026, 16:00 Eastern Time, based on the latest available closing data.

Key facts on Danaher stock

• Company: Danaher Corp.
• ISIN: US2358511028
• WKN: 866197
• Ticker: DHR
• Venue: NYSE
• Price (as of 06/17/2026, 16:00 Eastern Time): 177.85 USD
• Market cap: approximately 131,000,000,000 USD (as of 06/17/2026)
• Sector / Industry: Health Care - Life Sciences Tools & Services
• Index membership: Standard & Poor's 500 index
• Next earnings date: not officially scheduled

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.